BN Business News
Add your company to Business Communicator →

Business · 22/11/20261 min read

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

SHANGHAI, Nov. 22, 2026 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces the clinical data from CT1182 (KJ-C2529), a CD19/CD20-targeting in vivo CAR T-cell product candidate developed on...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →